Stay updated on Nivolumab for IDH Mutant Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.

Latest updates to the Nivolumab for IDH Mutant Gliomas Clinical Trial page
- Check4 days agoChange DetectedThe page now includes a consolidated Locations section listing Florida, Massachusetts, and New York sites, replacing the previous separate location pages for these sites.SummaryDifference0.4%

- Check11 days agoChange DetectedA new citation is added in Publications: Snyder et al., 2014 NEJM on CTLA-4 blockade in melanoma. The Erratum reference for that paper is removed.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision: v3.3.2 was added and v3.3.1 removed; this is a minor site maintenance update and does not alter study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check32 days agoChange DetectedA bibliographic citation in the Publications section was added and an older version of the same citation was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedThe government funding/operating status notice is removed from the page; trial details, eligibility, and outcomes remain the same.SummaryDifference0.4%

- Check47 days agoChange DetectedThe page now includes posted results (Results First Posted/Submitted) and a new PDF for the Study Protocol and SAP; enrollment and completion dates are updated and the study status is now Completed.SummaryDifference2%

Stay in the know with updates to Nivolumab for IDH Mutant Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.